CN111494803A - Portable control system and method for insulin - Google Patents
Portable control system and method for insulin Download PDFInfo
- Publication number
- CN111494803A CN111494803A CN202010328728.2A CN202010328728A CN111494803A CN 111494803 A CN111494803 A CN 111494803A CN 202010328728 A CN202010328728 A CN 202010328728A CN 111494803 A CN111494803 A CN 111494803A
- Authority
- CN
- China
- Prior art keywords
- insulin
- user
- machine
- micro
- blood information
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 170
- 102000004877 Insulin Human genes 0.000 title claims abstract description 85
- 108090001061 Insulin Proteins 0.000 title claims abstract description 85
- 229940125396 insulin Drugs 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 98
- 210000004369 blood Anatomy 0.000 claims abstract description 98
- 108010049140 Endorphins Proteins 0.000 claims abstract description 70
- 102000009025 Endorphins Human genes 0.000 claims abstract description 70
- 230000003914 insulin secretion Effects 0.000 claims abstract description 66
- 230000004936 stimulating effect Effects 0.000 claims abstract description 39
- 238000001514 detection method Methods 0.000 claims abstract description 33
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000741 silica gel Substances 0.000 claims abstract description 30
- 229910002027 silica gel Inorganic materials 0.000 claims abstract description 30
- 230000000638 stimulation Effects 0.000 claims abstract description 28
- 210000004556 brain Anatomy 0.000 claims abstract description 24
- 230000005764 inhibitory process Effects 0.000 claims description 28
- 230000028327 secretion Effects 0.000 claims description 24
- 238000003860 storage Methods 0.000 claims description 18
- 238000004891 communication Methods 0.000 claims description 9
- 230000035939 shock Effects 0.000 claims description 3
- 210000001186 vagus nerve Anatomy 0.000 description 23
- 238000001467 acupuncture Methods 0.000 description 16
- 230000001515 vagal effect Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000036772 blood pressure Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 4
- 230000036471 bradycardia Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 208000010496 Heart Arrest Diseases 0.000 description 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000003284 homeostatic effect Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 3
- 230000004899 motility Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000001013 sinoatrial node Anatomy 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 101800005049 Beta-endorphin Proteins 0.000 description 2
- 206010009866 Cold sweat Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010047141 Vasodilatation Diseases 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000001746 atrial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WOPZMFQRCBYPJU-NTXHZHDSSA-N beta-endorphin Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C1=CC=CC=C1 WOPZMFQRCBYPJU-NTXHZHDSSA-N 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000005176 gastrointestinal motility Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002336 repolarization Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 description 1
- 208000031814 IgA Vasculitis Diseases 0.000 description 1
- 206010056367 Joint tuberculosis Diseases 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 208000009360 Osteoarticular Tuberculosis Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 241000287181 Sturnus vulgaris Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000002057 chronotropic effect Effects 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000010292 electrical insulation Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000036279 refractory period Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 208000003001 spinal tuberculosis Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/02—Radiation therapy using microwaves
- A61N5/022—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6802—Sensor mounted on worn items
- A61B5/681—Wristwatch-type devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H23/00—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms
- A61H23/02—Percussion or vibration massage, e.g. using supersonic vibration; Suction-vibration massage; Massage with moving diaphragms with electric or magnetic drive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H39/00—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
- A61H39/06—Devices for heating or cooling such points within cell-life limits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
- A61N2/004—Magnetotherapy specially adapted for a specific therapy
- A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/02—Radiation therapy using microwaves
- A61N5/022—Apparatus adapted for a specific treatment
- A61N5/025—Warming the body, e.g. hyperthermia treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/02—Characteristics of apparatus not provided for in the preceding codes heated or cooled
- A61H2201/0207—Characteristics of apparatus not provided for in the preceding codes heated or cooled heated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/12—Driving means
- A61H2201/1207—Driving means with electric or magnetic drive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2205/00—Devices for specific parts of the body
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Rehabilitation Therapy (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Optics & Photonics (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Electrotherapy Devices (AREA)
Abstract
The invention provides a portable insulin control system and a method. An insulin side control system, comprising: the integrated machine comprises an integrated machine body, a detection bracelet and a silica gel sheet; the detection bracelet is used for acquiring blood information of a user in real time. Detect bracelet and all-in-one wireless connection, with blood information input all-in-one, judge the insulin secretion volume of needs according to blood information, send the stimulation signal of telecommunication. Both the detection bracelet and the all-in-one machine can be connected with an external terminal; the silica gel sheet is connected with the all-in-one machine and used for receiving the stimulating electric signal and stimulating the user to secrete endorphin so as to increase the insulin secretion amount in the body of the user; wherein, the silica gel sheet is attached on the reflecting point of the human body corresponding to the endorphin secreted by the brain.
Description
Technical Field
The invention relates to the technical field of insulin control equipment, in particular to a portable insulin control system and method.
Background
At present, no matter whether a patient measures the blood sugar by himself or measures the blood sugar in a hospital, the control means of the insulin holding amount in the human body can not make a needle to see blood, the skin is punctured by injecting the insulin, the scene of the injection is like a blood stranguria ground, pain and trouble are brought to the patient, vicious circle is caused, and the patient can not pull out the blood. In order to supplement the insufficient insulin holding amount in the body, the patient usually takes an injection to make insulin secretion. If the vagus nerve is excited, the insulin secretion can be promoted, which means that the endogenous means of the human body can replace the exogenous means of one-needle blood breakthrough.
In the literature, "what affects insulin secretion" is published in Chinese by unknown authors in 2017, 10 and 11 months. In this context, it is mentioned that: "what are the factors affecting insulin secretion? The state of free nerve function can affect insulin secretion. Promoting insulin secretion when vagus nerve is excited; when sympathetic nerve is excited, insulin secretion is inhibited. "this is the original of the author himself following the real experience. From this phenomenon with regularity, it is found that stimulation of vagal stimulation promotes insulin secretion. This should be said to eventually uncover a path through which the controllable human insulin holding capacity was not discovered.
However, studies have shown that: the stimulation of the vagus nerve has more favorable stimulation defect, namely the stimulation of the vagus nerve can cause the blood pressure to drop rapidly, and the aversion to human bodies is difficult to avoid. The expression is as follows: slow heart rate, vasodilatation, blood pressure drop, rapid gastrointestinal motility, abdominal pain due to smooth muscle spasm, nausea, emesis, pale complexion, cold sweat, emesis, bradycardia, arrhythmia, syncope, convulsion, and even cardiac arrest.
Therefore, it is urgently needed to find the site in the human body having the same function as the vagus nerve. The function of increasing insulin secretion can be realized only by stimulating endorphins, and the endorphin chemical substances can be activated and secreted to the whole body only by transmitting various waves such as micro-waves and the like to the endorphin system and matching various carriers. Control of insulin in vivo is achieved, however, specific endorphin stimulating devices and systems do not exist in the prior art. Therefore, how to stimulate endorphins in the brain and increase insulin secretion by hardware devices and running systems is a problem to be solved by the invention.
Disclosure of Invention
The invention provides a portable insulin control system and a portable insulin control method, which are used for solving the problem of increasing insulin secretion by stimulating endorphin through a hardware device and an operation system.
The invention provides an insulin portable control system, comprising: the integrated machine comprises an integrated machine body, a detection bracelet and a silica gel sheet;
the detection bracelet is used for acquiring blood information of a user in real time;
the detection bracelet is wirelessly connected with the all-in-one machine, the blood information is input into the all-in-one machine, and the all-in-one machine judges the required insulin secretion amount according to the blood information and sends out stimulation micro-waves;
the detection bracelet and the all-in-one machine can be connected with an external terminal;
the silica gel sheet is connected with the all-in-one machine, and is used for receiving the stimulation electrical signal, stimulating the user to secrete endorphins, and increasing the insulin secretion amount in the body of the user through the endorphins; wherein,
the silica gel sheet is attached to a reflection point on a human body, which corresponds to endorphin secretion of the brain, and sends out a micro-wave for stimulating the brain to secrete the endorphin.
As an embodiment of the present invention: the detection bracelet comprises a blood information sensor and a first wireless communicator; wherein,
the blood information sensor is connected with a first wireless communicator, and the first wireless communicator is used for transmitting the blood information acquired by the blood information sensor to the all-in-one machine; wherein,
the blood information sensor is used for acquiring blood information;
the blood information is blood sugar information in the body of the user;
the first wireless communicator comprises one or more of a WIFI transceiver, a Bluetooth module and an 3/4G module;
when the first wireless communicator is in wireless connection with the external terminal, the first wireless communicator transmits the blood sugar information to the external terminal, and the external terminal intelligently controls the all-in-one machine according to the blood sugar information; wherein,
and an APP for intelligently controlling the all-in-one machine is arranged in the external terminal.
As an embodiment of the present invention: the all-in-one machine comprises:
a housing;
the surface of the shell is provided with a key for receiving an instruction input by a user;
the inside of casing is provided with: the device comprises a processor, a micro-wave generator, a first controller, a smell generator, a second controller and a wireless communication module; wherein,
the micro-wave generator is connected with the first controller, the first controller is connected with the processor, the processor is used for sending a switch control command to the first controller according to an instruction input by the user, and the first controller controls the micro-wave generator to be turned on or turned off according to the switch control command;
the odor generator is connected with the second controller, the second controller is connected with the processor, and the second controller is used for controlling the odor generator to be turned on or off according to the processor control instruction;
the processor is also connected with the wireless communication module, and the wireless communication module is also used for being wirelessly connected with the detection bracelet and an external mobile terminal;
the surface of the shell is also provided with an output device, the output device is connected with the micro-wave generator, and the output device is used for outputting the micro-waves generated by the micro-wave generator;
the surface of the shell is also provided with a reminding device, the reminding device is connected with the processor, and the reminding device is used for reminding the user of increasing insulin secretion;
the surface of the shell is also provided with a micro-wave transmitting pen storage cavity, the micro-wave transmitting pen storage cavity is used for storing a micro-wave transmitting pen, and the micro-wave transmitting pen is connected with the micro-wave transmitter;
the surface of the shell is also provided with a magnetic patch storage cavity, and the magnetic patch storage cavity is taken as an embodiment of the invention: the output device includes:
the output interface is arranged on the surface of the shell;
and the output line is connected with the output interface and the silica gel sheet.
As an embodiment of the present invention: the all-in-one machine comprises: a skin vibration wand; wherein,
the skin vibration stick is stored in the vibration stick storage cavity;
the shock rod storage cavity is arranged on the surface of the shell.
An insulin on-body control method, comprising:
acquiring blood information of a user in real time according to the detection bracelet;
inputting the blood information into an all-in-one machine, and judging the insulin secretion amount required by the user by the all-in-one machine according to the blood information of the user; generating a micro-wave for stimulating the user to secrete endorphin according to the insulin secretion amount required by the user;
and attaching the micro-wave input to a silica gel sheet of a reflection point of endorphin secreted by the brain of the user, wherein the micro-wave stimulates a human body to secrete the endorphin through the silica gel sheet, and the secretion of the insulin of the human body is driven by the increase of the endorphin.
As an embodiment of the present invention: the real-time blood information who obtains the user according to detecting the bracelet includes:
acquiring blood information of the user through a blood information sensor; wherein,
the blood information is blood sugar information in the body of the user;
transmitting the blood information to the all-in-one machine and an external control terminal;
and the external control terminal intelligently controls the all-in-one machine through an APP program preset by the external control terminal according to the received blood information.
As an embodiment of the present invention: the all-in-one machine judges the insulin secretion amount required by the user according to the blood information of the user, and the step of generating the micro-waves for stimulating the user to secrete endorphins comprises the following steps:
the all-in-one machine judges the insulin inhibition value in the body of the user according to the received blood information;
the all-in-one machine acquires an insulin secretion value which needs to be increased by the user according to the insulin inhibition value in the body of the user;
the all-in-one machine generates micro-waves for stimulating the human body to secrete insulin according to the insulin secretion value required to be increased by the user;
as an embodiment of the present invention: the all-in-one machine judges the insulin secretion amount required by the user according to the blood information of the user, and generates the micro-waves for stimulating the user to secrete endorphins according to the insulin secretion amount required by the user, and the all-in-one machine further comprises:
dividing the inhibition value of the insulin in the body of the user into 100 point levels according to an insulin dividing mode preset in the all-in-one machine, and establishing an insulin inhibition value dividing model;
acquiring an insulin inhibition value of the user according to the received blood information, and marking the insulin inhibition value in the insulin inhibition value division model;
acquiring an insulin secretion value needing to be increased according to the insulin inhibition value;
establishing a control instruction according to the insulin secretion value;
and sending out the micro-wave according to the control command.
The invention has the beneficial effects that: side effects associated with stimulation of the vagus nerve can be substantially avoided; secondly, the complex restriction of measuring blood sugar and injecting insulin is removed for the patient; thirdly, providing omnibearing sense of participation for the patient to condition the insulin and exerting the subjective motility of the patient; fourthly, medical expense investment is saved; finally, insulin homeostatic replacement of in vitro intervention is an advance in scientific methodology.
Additional features and advantages of the invention will be set forth in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The objectives and other advantages of the invention will be realized and attained by the structure particularly pointed out in the written description and drawings.
The technical solution of the present invention is further described in detail by the accompanying drawings and embodiments.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention. In the drawings:
FIG. 1 is a diagram of a structure according to an embodiment of the present invention;
FIG. 2 is a flow chart of a method in an embodiment of the invention;
FIG. 3 is a schematic diagram of an all-in-one machine in an embodiment of the invention;
fig. 4 is a schematic diagram of another all-in-one machine in the embodiment of the invention.
Detailed Description
The preferred embodiments of the present invention will be described in conjunction with the accompanying drawings, and it will be understood that they are described herein for the purpose of illustration and explanation and not limitation.
In the present invention, the principle of increasing insulin secretion by a user by stimulating endorphins was discovered in 1977 based on endorphins and this discovery was awarded to the Nobel prize in physiology and medicine.the poor idea of endorphins' ability to stimulate insulin secretion in patients was based on the argument "β -endorphins can stimulate insulin secretion in diabetic patients".
Fig. 1 shows a structure diagram of an insulin personal control system, which includes: the integrated machine comprises an integrated machine 1, a detection bracelet 2 and a silica gel sheet 3;
the detection bracelet 2 is used for acquiring blood information of a user in real time;
the detection bracelet 2 is wirelessly connected with the all-in-one machine 1, the blood information is input into the all-in-one machine 1, the all-in-one machine 1 judges the required insulin secretion amount according to the blood information and sends out stimulation micro-waves;
the detection bracelet 2 and the all-in-one machine 1 can be connected with an external terminal;
the silica gel sheet is connected with the all-in-one machine, and is used for receiving the stimulation electrical signal, stimulating the user to secrete endorphins, and increasing the insulin secretion amount in the body of the user through the endorphins; wherein,
the silica gel sheet is attached to a reflection point on a human body, which corresponds to endorphin secretion of the brain, and sends out a micro-wave for stimulating the brain to secrete the endorphin.
When the method is used in practice, as long as a user stares at the inhibited value of the insulin on the interface of the external terminal control equipment with two eyes, the inhibited value of the insulin can be seen from the interface of the smart phone to gradually decrease until the value is reduced to be below 31 point levels by adopting fragmentation time operation according to endorphin recharging measures built in the insulin-associated controller. Secondly, an in vivo conditioning mechanism is used, namely, endorphin chemical substances in the body are moved to the position where the endorphin chemical substances need to play a role, so that the equilibrium state of insulin is achieved, and the injection and the intervention of any foreign substances are not needed.
The silica gel sheet is called as a heat-conducting silica gel sheet. When the electronic appliance is used, moisture resistance, dust resistance and corrosion resistance are required, and the heat-conducting silica gel sheet is produced accordingly. It is an organosilicon material, can be widely applied to various electronic products, thereby ensuring the stability of electrical properties.
The function of heat conduction silica gel piece is as follows:
firstly, the heat-conducting silica gel sheet is a high heat-conducting insulating organic silicon material.
Secondly, the heat conduction silica gel piece has high thermal conductivity, splendid heat conductivity, good electrical insulation, the service temperature of broad, fine stability in use, lower consistency and good workability.
And thirdly, the heat-conducting silica gel sheet can be kept in a state of being used for a long time at the temperature of between 50 ℃ below zero and 230 ℃.
And fourthly, the heat-conducting silica gel sheet has low oil separation degree (tending to zero), and is resistant to high and low temperatures, water, ozone and weather aging.
Since the media report of 07/28/2004, 4 acupuncture points with drug-dropping effect were found on human body! By stimulating them with low-frequency electric pulses, the relapse rate of drug addicts after drug withdrawal is reduced to 70%, which is almost one hundred percent at present. The low-frequency electric pulse stimulation is implemented by using heat-conducting silica gel sheet applied to Neiguan acupoint, Waiguan acupoint, Laogong acupoint and Hegu acupoint. Professor Korean Jinsheng of neuroscience research institute of department of medicine of Chinese academy of sciences and Beijing university finds that the 4 acupuncture points are stimulated by low-frequency electric pulses to promote the brain of the drug addict to recover and generate 'self-made morphine' called 'opium peptide', so that the drug addict gradually gets rid of dependence on drugs and abstains from drug addiction. The use of heat-conducting silicone sheets has been internationally agreed.
The all-in-one machine is a portable device for sending out the micro-waves to stimulate the brain to secrete the endorphins, judges the amount of insulin needed to be secreted by a user through blood information, sends out corresponding stimulating micro-waves according to the amount of the insulin needed to be secreted by the user, continuously stimulates the brain of a human body to secrete the endorphins, and stops sending out the stimulating micro-waves until the amount of the insulin needed to be secreted by the user is produced by stimulating the human body to be secreted by the endorphins secreted by the brain of the human body.
The human insulin inhibited value is divided into 100 point levels and is drawn into a circular chart. The patient wears a sensor for collecting blood information on the wrist. App connects the sensor to a cell phone above iPhone4 (some chinese products are smart phones compatible with 37 degree bracelets). The blood information collected by the sensor is transmitted to a mobile phone above iPhone4, and the mobile phone is provided with a digital information analysis system. The analysis result is expressed by the number of points of the insulin inhibition value on the circular graph. The point scale values are displayed on the phone screen above iPhone4, and only about 5 minutes is required to see the fatigue values on the smartphone interface (31-100 point scales). The fatigue number is the insulin inhibited value.
The invention has the beneficial effects that: side effects associated with stimulation of the vagus nerve can be substantially avoided; secondly, the complex restriction of measuring blood sugar and injecting insulin is removed for the patient; thirdly, providing omnibearing sense of participation for the patient to condition the insulin and exerting the subjective motility of the patient; fourthly, medical expense investment is saved; finally, insulin homeostatic replacement of in vitro intervention is an advance in scientific methodology.
As an embodiment of the present invention: the detection bracelet comprises a blood information sensor,
A first wireless communicator; wherein,
the blood information sensor is connected with a first wireless communicator, and the first wireless communicator is used for transmitting the blood information acquired by the blood information sensor to the all-in-one machine; wherein,
the blood information sensor is used for acquiring blood information;
the blood information is blood sugar information in the body of the user;
the first wireless communicator comprises one or more of a WIFI transceiver, a Bluetooth module and an 3/4G module;
when the first wireless communicator is in wireless connection with the external terminal, the first wireless communicator transmits the blood sugar information to the external terminal, and the external terminal intelligently controls the all-in-one machine according to the blood sugar information; wherein,
and an APP for intelligently controlling the all-in-one machine is arranged in the external terminal.
In addition, the detection bracelet can also adopt a 37-degree bracelet of a sold electronic product. The bracelet is compatible with various smart phones, particularly smart phones above iPhone 4. One of the functions of the '37-degree second-generation bracelet' is to detect 'fatigue', and the bracelet detects 'fatigue' through blood information and is irrelevant to the 'insulin portable control system and insulin portable control method' patent application of the inventor. Incidentally, the data displayed by "fatigue" corresponds to the data of "pain hormone" referred to in the present invention. I change 100 grids in a numerical graph of 'fatigue' displayed by a 37-degree second-generation bracelet into 100 'point levels', wherein 31-100 point levels belong to risk point levels.
As an embodiment of the present invention: as shown in fig. 3, the all-in-one machine includes:
a housing 21;
the surface of the shell is provided with a key 22 for receiving an instruction input by a user;
the inside of the housing 21 is provided with: a processor 26, a micro-wave generator 23, a first controller 24, a scent generator 28, a second controller 29 and a wireless communication module 27; wherein,
the micro-wave generator 23 is connected to the first controller 24, the first controller 24 is connected to the processor 26, the processor 26 is configured to send a switch control command to the first controller 24 according to the instruction input by the user, and the first controller 24 controls the micro-wave generator 23 to be turned on or off according to the switch control command; the micro-wave is a means of stimulating human acupuncture points, and promotes the human brain to generate endorphin by stimulating the human acupuncture points. The microwave generator is a point detecting (culintDetector) pen. It is a technology developed according to the physiological and pathological conditions of body and the physical and biological characteristics of some acupoints to objectively display acupoints and auxiliarily emit micro-electric waves. The electrical detection of acupuncture points includes resistance (electric conductivity) detection and potential detection of acupuncture points. Decades of research results show that the meridian point has low resistance and high potential electrical characteristics, and according to the characteristics, researchers develop various meridian point detectors. At present, the instrument is widely applied to the channels and acupoints resistance detector in China. The working principle is as follows: the acupoint resistance detector measuring device mainly comprises a direct current type and an alternating current type. With the continuous improvement of recent years, the skin resistance or the electric conduction quantity is mainly measured by alternating current and pulse current at present, so that the polarization effect of the current on the skin can be reduced, and characteristics (capacitance, inductance and the like) except the skin resistance can also be measured. The principle of the detection pen is as follows: when a certain current passes through the ammeter and is connected to the surface of the human body acupuncture points or non-acupuncture points, areas which are easy to be electrified and not easy to be electrified are arranged on the surface of the body, so that the impedance difference is shown, the difference can be displayed through the ammeter between a detected area and a power supply, and if the current quantity displayed by the ammeter is large, the areas are low-resistance points; conversely, the point with small current is a high resistance point, so that the electrical characteristics of the meridian point and the non-meridian point can be reflected.
The odor generator 28 is connected with the second controller 29, the second controller 29 is connected with the processor 26, and the second controller 29 is used for controlling the odor generator 28 to be turned on or off according to the control instruction of the processor 26; the smell is also used as a means for stimulating the human body, and stimulates the cerebral cortex by stimulating the special aroma to promote the human brain to generate endorphin. For example, the fragrance of essential oils (such as lavender) can promote the secretion of endorphins by the human brain.
The processor 26 is further connected with the wireless communication module 27, and the wireless communication module 27 is further configured to be wirelessly connected with the detection bracelet and an external mobile terminal;
the surface of the shell 21 is further provided with an output device 25, the output device 25 is connected with the micro-wave generator 23, and the output device 25 is used for outputting the micro-wave generated by the micro-wave generator;
the surface of the shell 21 is further provided with a reminding device 30, the reminding device 30 is connected with the processor 26, and the reminding device 30 is used for reminding the user of increasing insulin secretion; the reminder device 30 includes: one or more of indicator light, buzzer, display and loudspeaker.
The surface of the shell 21 is also provided with a micro-wave transmitting pen storage cavity 33, the micro-wave transmitting pen storage cavity 33 is used for storing a micro-wave transmitting pen, and the micro-wave transmitting pen is connected with the micro-wave transmitter;
the surface of the housing is also provided with a magnetic patch storage cavity 32, the magnetic patch storage cavity 32. Magnetism is also used as a means of stimulating the human body, and stimulates the human body acupuncture points to promote the human brain to generate endorphin. The magnetic patch is made of various minerals and can play a role in invisible acupuncture. It features no need of needle, medicine and electricity, no wound and no cross infection, and can stimulate the reflecting points (acupoints) of human body to emit magnetic waves under the action of invisible acupuncture. The magnetic paster is an invisible acupuncture device, directionally activates endorphin in brain and secretes happy hormone chemical substances to reach the whole body, and plays an invisible silver needle effect. The mineral substance of the magnetic patch is subjected to solid phase reaction superfine grinding, nanoparticle modification, coordination with magnesium, iron, germanium and other composite elements, and is added with a special connecting agent and an embedding agent for mixing and molding, and then is subjected to precise temperature rise, heat preservation and cold treatment to prepare the composite crystal wafer with special reactivity. It has the following advantages: the nano polar crystal has the energy gathering effect, has obvious acupuncture feeling and burning sensation, and has the effect similar to the stimulation acupuncture point produced by the traditional acupuncture stimulation acupuncture point.
As an embodiment of the present invention: the output device 25 includes:
the output interface is arranged on the surface of the shell;
and the output line is connected with the output interface and the silica gel sheet.
As an embodiment of the present invention: the all-in-one machine device includes: a skin vibration wand; wherein,
the skin vibrator is stored in a vibrator storage chamber 34;
the shock rod storage chamber 34 is provided in the surface of the housing 21.
Vibration is also used as a means of stimulating the human body by stimulating the skin to promote endorphin production by the human brain. The skin vibration stick is internally provided with a vibration motor which generates high-frequency vibration and applies the high-frequency vibration to the skin of a human body.
As shown in fig. 2: an insulin on-body control method, comprising:
step 100: acquiring blood information of a user in real time according to the detection bracelet;
step 101: inputting the blood information into an all-in-one machine, and judging the insulin secretion amount required by the user by the all-in-one machine according to the blood information of the user; generating a micro-wave for stimulating the user to secrete endorphin according to the insulin secretion amount required by the user;
step 102: and attaching the micro-wave input to a silica gel sheet of a reflection point of endorphin secreted by the brain of the user, wherein the micro-wave stimulates a human body to secrete the endorphin through the silica gel sheet, and the secretion of the insulin of the human body is driven by the increase of the endorphin.
As an embodiment of the present invention: the real-time blood information who obtains the user according to detecting the bracelet includes:
acquiring blood information of the user through a blood information sensor; wherein,
the blood information is blood sugar information in the body of the user;
transmitting the blood information to the all-in-one machine and an external control terminal;
and the external control terminal intelligently controls the all-in-one machine through an APP program preset by the external control terminal according to the received blood information.
As an embodiment of the present invention: the all-in-one machine judges the insulin secretion amount required by the user according to the blood information of the user, and the step of generating the micro-waves for stimulating the user to secrete endorphins comprises the following steps:
the all-in-one machine judges the insulin inhibition value in the body of the user according to the received blood information;
the all-in-one machine acquires an insulin secretion value which needs to be increased by the user according to the insulin inhibition value in the body of the user;
the all-in-one machine generates micro-waves for stimulating the human body to secrete insulin according to the insulin secretion value required to be increased by the user;
as an embodiment of the present invention: the all-in-one machine judges the insulin secretion amount required by the user according to the blood information of the user, and generates the micro-waves for stimulating the user to secrete endorphins according to the insulin secretion amount required by the user, and the all-in-one machine further comprises:
dividing the inhibition value of the insulin in the body of the user into 100 point levels according to an insulin dividing mode preset in the all-in-one machine, and establishing an insulin inhibition value dividing model;
acquiring an insulin inhibition value of the user according to the received blood information, and marking the insulin inhibition value in the insulin inhibition value division model;
acquiring an insulin secretion value needing to be increased according to the insulin inhibition value;
establishing a control instruction according to the insulin secretion value;
and sending out the micro-wave according to the control command.
The principle adopted in the invention is as follows:
the patient can see the insulin suppressed value from the display interface of the mobile control terminal such as a smart phone. To expel the suppressed insulin level in the body, the patient begins a game. The loading is performed according to endorphin loading measures so as to increase the insulin secretion value in vivo. As the value of insulin secretion increases, the value of insulin inhibition decreases accordingly. The eliminated chemical substances with the insulin inhibition value are discharged out of the body as waste through the kidney within 24 hours.
To stimulate vagal excitation to promote insulin secretion, retrieved from the internet: the two extreme opposite phenomena, insulin secretion is promoted when the vagus nerve is excited, and insulin secretion is inhibited when the sympathetic nerve is excited. This discussion comes from: in the book of "what affects insulin secretion", unknown authors published in 2017 in Chinese 10, 11. In this context, it is mentioned that: "what are the factors affecting insulin secretion? The state of free nerve function can affect insulin secretion. Promoting insulin secretion when vagus nerve is excited; when sympathetic nerve is excited, insulin secretion is inhibited. "this is the original of the author himself following the real experience. From this phenomenon with regularity, it is found that stimulation of vagal stimulation promotes insulin secretion. This should be said to eventually uncover a path through which the controllable human insulin holding capacity was not discovered.
[ in vivo Conditioning can be used to replace the first needle break ] patients usually take injection to induce insulin secretion in order to supplement the insufficient insulin holding capacity in vivo. If the vagus nerve is excited, the insulin secretion can be promoted, which means that the endogenous means of the human body can replace the exogenous means of one-needle blood breakthrough.
The stimulation of vagus nerve leads to rapid blood pressure drop, and the malignant effect on human body is difficult to avoid. The expression is as follows: slow heart rate, vasodilatation, blood pressure drop, accelerated gastrointestinal motility, abdominal pain due to smooth muscle spasm, nausea, emesis, pale complexion, cold sweat, emesis, bradycardia, arrhythmia, syncope, convulsion, and even cardiac arrest.
In addition, people who are not eligible to stimulate the vagus nerve are more extensive, such as: people with severe heart, liver, kidney and lung disease; malignant tumor, pernicious anemia, people with prolonged illness and infirmity; patients with thrombocytopenic purpura or anaphylactoid purpura are unable to stimulate casually; patients with large areas of skin or patients with ulcerative dermatitis; patients with influenza, encephalitis, meningitis, diphtheria, dysentery, and other acute infectious diseases; acute inflammation patients, such as acute suppurative tonsillitis, pneumonia, acute appendicitis, cellulitis, etc., and some chronic inflammation patients, such as limb joint tuberculosis, spinal tuberculosis, osteomyelitis, etc.
The principle of deep interpretation that rapid blood pressure drop can occur when the vagus nerve is stimulated is as follows: first, the vagus nerve contains sensory, motor, and parasympathetic fibers. The transmitters released by these fiber terminals are acetylcholine, which binds to M choline receptors on the myocardial cell membrane and can cause a slowing of heart rate, a weakening of atrial myocontraction force, a shortening of atrial muscle refractory period, a slowing of atrioventricular conduction velocity, and even an atrioventricular conduction block, i.e. negative chronotropic, inotropic, and rheostatic effects. In general, the right vagus nerve dominates the sinoatrial node, while the left vagus nerve dominates the atrioventricular conduction system. Second, the right vagus nerve is stimulated, with the acetylcholine released from its periphery: on one hand, the K + outflow of the sinoatrial node cells is increased in the repolarization process, and the absolute value of the maximum repolarization potential is increased as a result; on the other hand, the auto-depolarization rate is slowed down. Both of these factors cause the sinus node to become less autonomic, and thus slower, and lower blood pressure. When the stimulation intensity is increased, sinus asystole can even appear, so that the blood pressure is rapidly reduced.
The inventor finds that the vagus nerve has a neighbor in the brain to be competent for the disadvantage and to be capable of stimulating the vagus nerve for the disadvantage, the neighbor is the well-known endorphin hormone, the endorphin is discovered and awarded with the nobel physiology and medicine prize in 1977, the endorphin has the ability to overcome the disadvantage, β -endorphin stimulates the secretion of insulin of the diabetic patient, the data is introduced from the international medical science, the clinical biochemistry and laboratory test science section, 1985, the author, the schooling β -endorphin is included in the endorphin.
[ Nerphin stimulating measures ] Nerphin is stimulated, and a chemical substance of Nerphin can be activated and secreted to the whole body by only transmitting various waves such as micro-waves and the like to a Nerphin system and matching various carriers.
Endorphins and vagus nerves are the source of pleasure in the brain, but the quality of endorphins and vagus nerves is greatly different due to different sources. The former is of high quality, the latter is of low quality.
[ superiority of endorphins for stimulation ] the role of endorphin stimulation is well-balanced with that of vagus nerve. Then where is the predominance of stimulating endorphins? First, side effects associated with stimulation of the vagus nerve are substantially avoided; secondly, the complex restriction of measuring blood sugar and injecting insulin is removed for the patient; thirdly, providing omnibearing sense of participation for the patient to condition the insulin and exerting the subjective motility of the patient; fourthly, medical expense investment is saved; finally, insulin homeostatic replacement of in vitro intervention is an advance in scientific methodology.
Endorphin secretion instead of vagal secretion has disadvantages but solutions are possible because endorphin secretion cannot completely replace the disadvantages resulting from stimulation of vagal secretion, since stimulation of endorphin secretion also brings a small amount of vagal secretion by the way. As a result, the amount of the original insulin-inhibitory value in the body is increased by the incorporation of a small amount of vagal secretion brought about by endorphin secretion. At this time, the situation is changed, the insulin inhibited value of the "rat" is increased, and the endorphin secretion value of the "cat" is required to be more powerful to eliminate the increased "rat". The insulin inhibition value decreases gradually with endorphin secretion (interspersed with vagal secretion). The situation is necessarily such that (endorphin secretion is accompanied by vagal secretion) increases the decrease (insulin inhibited value), which means that the risk of a decrease in blood pressure in a patient caused by stimulation of vagal secretion is also eliminated.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Claims (9)
1. An insulin on-board control system, comprising: the integrated machine comprises an integrated machine body, a detection bracelet and a silica gel sheet;
the detection bracelet is used for acquiring blood information of a user in real time;
the detection bracelet is wirelessly connected with the all-in-one machine, the blood information is input into the all-in-one machine, and the all-in-one machine judges the required insulin secretion amount according to the blood information and sends out stimulation micro-waves;
the detection bracelet and the all-in-one machine can be connected with an external terminal;
the silica gel sheet is connected with the all-in-one machine, and is used for receiving the stimulating micro-waves, stimulating the user to secrete endorphins, and increasing the insulin secretion amount in the body of the user through the endorphins; wherein,
the silica gel sheet is attached to a reflection point, corresponding to endorphin secretion of the brain, on the human body, and the received stimulation micro-waves are output to the brain of the human body, so that the brain is stimulated to secrete the endorphin.
2. An insulin on-body control system according to claim 1, wherein the detection bracelet comprises a blood information sensor and a first wireless communicator; wherein,
the blood information sensor is connected with a first wireless communicator, and the first wireless communicator is used for transmitting the blood information acquired by the blood information sensor to the all-in-one machine; wherein,
the blood information sensor is used for acquiring blood information;
the blood information is blood sugar information in the body of the user;
the first wireless communicator comprises one or more of a WIFI transceiver, a Bluetooth module and an 3/4G module;
when the first wireless communicator is in wireless connection with the external terminal, the first wireless communicator transmits the blood sugar information to the external terminal, and the external terminal intelligently controls the all-in-one machine to send out the stimulation micro-waves according to the blood sugar information; wherein,
the intelligent control is arranged in the external terminal, and the all-in-one machine sends out APP stimulating micro-waves.
3. An insulin on-board control system as claimed in claim 1, wherein said all-in-one machine comprises:
a housing;
the surface of the shell is provided with a key for receiving an instruction input by a user;
the inside of casing is provided with: the device comprises a processor, a micro-wave generator, a first controller, a smell generator, a second controller and a wireless communication module; wherein,
the micro-wave generator is connected with the first controller, the first controller is connected with the processor, the processor is used for sending a switch control command to the first controller according to an instruction input by the user, and the first controller controls the micro-wave generator to be turned on or turned off according to the switch control command;
the odor generator is connected with the second controller, the second controller is connected with the processor, and the second controller is used for controlling the odor generator to be turned on or off according to the processor control instruction;
the processor is also connected with the wireless communication module, and the wireless communication module is also used for being wirelessly connected with the detection bracelet and an external mobile terminal;
the surface of the shell is also provided with an output device, the output device is connected with the micro-wave generator, and the output device is used for outputting the micro-waves generated by the micro-wave generator;
the surface of the shell is also provided with a reminding device, the reminding device is connected with the processor, and the reminding device is used for reminding the user of increasing insulin secretion;
the surface of the shell is also provided with a micro-wave transmitting pen storage cavity, the micro-wave transmitting pen storage cavity is used for storing a micro-wave transmitting pen, and the micro-wave transmitting pen is connected with the micro-wave transmitter;
the surface of the shell is further provided with a magnetic patch storage cavity, the magnetic patch storage cavity is used for storing a magnetic patch, and the magnetic patch is connected with the processor.
4. An insulin on-body control system according to claim 3, wherein the output device comprises:
the output interface is arranged on the surface of the shell;
and the output line is connected with the output interface and the silica gel sheet.
5. An insulin on-body control system according to claim 3, wherein the all-in-one device comprises: a skin vibration wand; wherein,
the skin vibration stick is stored in the vibration stick storage cavity;
the shock rod storage cavity is arranged on the surface of the shell.
6. An insulin carry-on control method is characterized by comprising the following steps:
the detection bracelet acquires blood information of a user in real time;
the detection bracelet inputs the blood information into an all-in-one machine, and the all-in-one machine judges the insulin secretion amount required by the user according to the blood information of the user; generating a micro-wave for stimulating the user to secrete endorphin according to the insulin secretion amount required by the user;
the all-in-one machine is used for inputting and attaching the micro-waves to a silica gel sheet of a reflection point of endorphin secreted by the brain of the user, the micro-waves stimulate the human body to secrete the endorphin through the silica gel sheet, and the secretion of the insulin of the human body is driven by the increase of the endorphin.
7. The insulin carry-on control method according to claim 6, wherein the real-time obtaining of the blood information of the user according to the detection bracelet comprises:
the detection bracelet acquires blood information of the user through a blood information sensor; wherein,
the blood information is blood sugar information in the body of the user;
the detection bracelet transmits the blood information to the all-in-one machine and an external control terminal;
and the external control terminal intelligently controls the all-in-one machine through an APP program preset in the external control terminal according to the received blood information.
8. The system of claim 6, wherein the all-in-one machine determines the amount of insulin secretion required by the user according to the blood information of the user, and generates the micro-waves for stimulating the secretion of endorphins by the user according to the amount of insulin secretion required by the user comprises:
the all-in-one machine judges the insulin inhibition value in the body of the user according to the received blood information;
the all-in-one machine acquires an insulin secretion value which needs to be increased by the user according to the insulin inhibition value in the body of the user;
and the all-in-one machine generates micro-waves for stimulating the human body to secrete insulin according to the insulin secretion value which needs to be increased by the user.
9. The system of claim 6, wherein the integrated machine determines an amount of insulin secretion required by the user according to the blood information of the user, and generates the micro-waves for stimulating the secretion of endorphins by the user according to the amount of insulin secretion required by the user further comprises:
the all-in-one machine divides the inhibition value of the insulin in the body of the user into 100 point levels according to a preset insulin dividing mode, and establishes an insulin inhibition value dividing model;
the all-in-one machine acquires an insulin inhibition value of the user according to the received blood information and marks the insulin inhibition value in the insulin inhibition value division model;
the all-in-one machine acquires an insulin secretion value required to be increased according to the insulin inhibition value;
the all-in-one machine establishes a control instruction according to the insulin secretion value;
and the all-in-one machine sends out the micro-wave according to the control instruction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010328728.2A CN111494803A (en) | 2020-04-23 | 2020-04-23 | Portable control system and method for insulin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010328728.2A CN111494803A (en) | 2020-04-23 | 2020-04-23 | Portable control system and method for insulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111494803A true CN111494803A (en) | 2020-08-07 |
Family
ID=71877932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010328728.2A Pending CN111494803A (en) | 2020-04-23 | 2020-04-23 | Portable control system and method for insulin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111494803A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1736327A (en) * | 2005-07-21 | 2006-02-22 | 高春平 | Health-caring and therapeutic device controlled by brain wave signal |
| MXJL06000004A (en) * | 2003-10-27 | 2006-05-04 | Jorge Alberto Morales Sanchez | Device for emitting electric impulses directed to the brain. |
| CN1894000A (en) * | 2003-09-04 | 2007-01-10 | 梅塔库尔公司 | Blood glucose level control |
| CN101069769A (en) * | 2007-03-23 | 2007-11-14 | 南京济生医疗科技有限公司 | Needle-free pain-relieving instrument and its setting method |
| CN102139140A (en) * | 2011-04-27 | 2011-08-03 | 华南理工大学 | Transcranial micro-current stimulator with music function |
| CN104958835A (en) * | 2015-06-24 | 2015-10-07 | 华南理工大学 | Mobile electric pulse dysmenorrhoea therapeutic instrument |
| CN205964445U (en) * | 2016-03-21 | 2017-02-22 | 浙江中医药大学 | A acupuncture point electric stimulation device for assisting analgesia |
| CN107438398A (en) * | 2015-01-06 | 2017-12-05 | 大卫·伯顿 | Portable wearable monitoring system |
| CN108187184A (en) * | 2017-12-28 | 2018-06-22 | 大连医诚医用科技成果转移转化有限公司 | Novel artificial pancreas islet |
-
2020
- 2020-04-23 CN CN202010328728.2A patent/CN111494803A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1894000A (en) * | 2003-09-04 | 2007-01-10 | 梅塔库尔公司 | Blood glucose level control |
| MXJL06000004A (en) * | 2003-10-27 | 2006-05-04 | Jorge Alberto Morales Sanchez | Device for emitting electric impulses directed to the brain. |
| CN1736327A (en) * | 2005-07-21 | 2006-02-22 | 高春平 | Health-caring and therapeutic device controlled by brain wave signal |
| CN101069769A (en) * | 2007-03-23 | 2007-11-14 | 南京济生医疗科技有限公司 | Needle-free pain-relieving instrument and its setting method |
| CN102139140A (en) * | 2011-04-27 | 2011-08-03 | 华南理工大学 | Transcranial micro-current stimulator with music function |
| CN107438398A (en) * | 2015-01-06 | 2017-12-05 | 大卫·伯顿 | Portable wearable monitoring system |
| CN104958835A (en) * | 2015-06-24 | 2015-10-07 | 华南理工大学 | Mobile electric pulse dysmenorrhoea therapeutic instrument |
| CN205964445U (en) * | 2016-03-21 | 2017-02-22 | 浙江中医药大学 | A acupuncture point electric stimulation device for assisting analgesia |
| CN108187184A (en) * | 2017-12-28 | 2018-06-22 | 大连医诚医用科技成果转移转化有限公司 | Novel artificial pancreas islet |
Non-Patent Citations (1)
| Title |
|---|
| 杨明等: "《中医香疗学》", 31 August 2018 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100866378B1 (en) | A Low Frequency Magnetic Physical Treatment Device using Shumann Resonance Frequency, Water Molecule Resonance Frequency and Brain Waves as the Important Treatment Information | |
| US8968172B2 (en) | Handheld cell excitation terminal capable of dynamic optimization of therapeutic effect and remote therapeutic system | |
| CN205867307U (en) | Intermediate frequency physiotherapy equipment | |
| CN106730348A (en) | The smart machine and its control method of a kind of thermoelectricity acousto-optic therapeutic alliance | |
| CN204767042U (en) | Biological electric excitation therapies appearance of intelligence frequency conversion | |
| CN109731220A (en) | Super portable physiotherapy equipment | |
| EP3579916A1 (en) | Device for intracellular transport in resonance | |
| CN112022683B (en) | VR-based meridian point guiding device, system and method | |
| CN204767043U (en) | Biological electric excitation therapies appearance | |
| CN111494803A (en) | Portable control system and method for insulin | |
| KR20140102879A (en) | Electro-acupuncture system | |
| CN201441621U (en) | Multifunctional acupuncture instrument | |
| CN203244557U (en) | Sense rehabilitation training system with touch, temperature and vibration stimulation functions | |
| CN208017769U (en) | A kind of multifunctional moxibustion instrument | |
| CN204468592U (en) | A kind of multifunctional recovery bed based on somatosensory vibro-music relaxation therapy | |
| CN106038245A (en) | Intelligent composite sound wave meridian-dredging health instrument | |
| US20220062622A1 (en) | Vagal nerve stimulation therapy | |
| CN204637305U (en) | Diabetes detect and physical therapeutic system | |
| CN202844097U (en) | Remote monitoring acupoint press health care system | |
| CN209662444U (en) | Super portable physiotherapy equipment and beauty instrument, through cranium microcurrent stimulating instrument and massage device | |
| TWM552811U (en) | Acupuncture points electrotherapy device based on meridians sensing transmission | |
| CN203598360U (en) | Physiotherapy instrument with permanent magnet, and far-infrared-excitated germanite/jade | |
| CN205493826U (en) | Human skin resistance sensing display system | |
| CN110279943A (en) | A kind of limb rehabilitating modality | |
| CN206499776U (en) | Move Phototherapeutic instrument |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200807 |